MDT

The Ever-Expanding Potential
of Precision Medicine

Supporting oncology care teams in removing barriers to clinically actionable biomarker testing.

Explore Biomarker Testing Guidelines

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) inform biomarker testing.

Access quick-reference flow charts of National Comprehensive Cancer Network^® (NCCN^®) biomarker testing recommendations by tumor type:

Lung tumor guidelines^a

Breast tumor guidelines

Ovarian tumor guidelines

Prostate tumor guidelines

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

^aThis page contains content pertaining to non-small cell lung cancer (NSCLC) only.

NCCN, National Comprehensive Cancer Network.

The Biomarkers Informing Treatment Options

Many tumors contain actionable biomarkers . Testing unlocks this critical information, helping patients receive the right treatment for their unique cancer.

Select a biomarker below to view available diagnostic prevalence as well as practical information on how to test for them:

Lung Cancer

EGFRERBB2 (HER2)

Ovarian Cancer

HRD

Breast Cancer

BRCA1/2HER2PIK3CA/AKT1/PTEN

Prostate Cancer

HRRm, including BRCA1/2

AKT1, serine/threonine protein kinase 1; BRCA1/2, BReast CAncer susceptibility gene 1/2; EGFR, epidermal growth factor receptor; ERBB2, erb-b2 receptor tyrosine kinase 2; HER2, human epidermal growth factor receptor 2; HRD, homologous recombination deficiency; HRRm, homologous recombination repair gene mutation; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PTEN, phosphatase and tensin homolog.

Browse a selection of major laboratories offering a range of biomarker testing options.

Find a Testing Lab

Scientist dropping solution into test tube

This information is intended as educational and is not intended as a complete list of available testing options. AstraZeneca is not responsible for any test provider and does not endorse any particular diagnostic test. The accuracy and results of diagnostic tests vary, and AstraZeneca shall have no liability arising from such testing. Information provided herein should in no way be considered a guarantee of coverage, reimbursement, or patient assistance. Providers should contact third-party laboratories for information on their patient assistance programs. While diagnostic testing may assist providers in identifying appropriate treatment for patients, the decision and action should be decided by a provider in consultation with the patient. All products are trademarks of their respective holders, all rights reserved.

MDT Collaboration Maximizes Biomarker Testing Impact

Explore how MDT partnership can help improve testing and ensure that the promise of precision medicine is accessible to all communities.

Lab screen showing microscopic image of stained tumor cells

Keep up with the pace of precision medicine

Wherever you may be in your biomarker testing journey, stay current on recent technology advances in cancer detection and emerging biomarkers to support precision medicine in your practice.

Discover latest developments

Follow best practice in biomarker testing

Check out our best practices checklist for ways to shorten time to molecular testing results, coordinate care, and more.

Optimize your approach

MDT, multidisciplinary team.

Solutions for Common Biomarker Testing Challenges

Find actionable solutions to help overcome these common testing challenges faced by the MDT.

MDT, multidisciplinary team.

Helpful Resources

Check out these featured resources, designed to help the MDT support biomarker testing.

3:01 min

FOR PATIENTS

Gene mutations: Inherited vs. acquired

Understand the differences between inherited and acquired mutations, also known as germline and somatic mutations, and why testing may be recommended.

View more resources